Metabolic syndrome and insulin signaling in kidneyShoko Horita, George Seki*, Hideomi Yamada, Masashi Suzuki, Motonobu Nakamura and Toshiro Fujita
Department of Internal Medicine, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo Tokyo 113-0033, Japan
- corresponding Author:
- George Seki
Department of Internal Medicine, Faculty of Medicine
University of Tokyo,7-3-1 Hongo
Bunkyo-ku, Tokyo 113-0033, Japan
E-mail: [email protected]
Received Date: November 01, 2011; Accepted Date: November 30, 2011; Published Date: December 03, 2011
Citation: Horita S, Seki G, Yamada H, Suzuki M, Nakamura M, et al. (2011) Metabolic syndrome and insulin signaling in kidney. Endocrinol Metabol Syndrome S1:005. doi: 10.4172/2161-1017.S1-005
Copyright: © 2011 Horita S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Metabolic syndrome (MetS) is now recognized as a big threat for human health. It has been a problem in developed countries for decades and also emerging similarly in developing countries. It has been also called as “Syndrome X”, “Deadly quartet”, “Reaven’s syndrome”. Essentially these are of the same clinical status, in which insulin resistance is the common condition. In such condition hyperinsulinemia occurs, which may have potential influence on other organs and tissues, including kidney – glomeruli and tubules - , cardiovascular systems, liver, muscles. This review will focus on the influence of MetS on the point of insulin resistance and its influence of kidney, especially proximal tubules and glomeruli.